Department of Pharmacy, Sun Yat-sen University Affiliated Zhongshan Hospital, Zhongshan, 528403, Guangdong Province, China.
Department of Laboratory Medicine, Sun Yat-sen University Affiliated Zhongshan Hospital, Zhongshan, 528403, Guangdong Province, China.
Sci Rep. 2022 May 16;12(1):8030. doi: 10.1038/s41598-022-11260-2.
Atherosclerosis is the primary origin of acute coronary syndrome (ACS) diseases. Previous studies have shown that lncRNA plaque-enriched long noncoding RNA in atherosclerotic macrophage regulation (lncRNA PELATON) is a specific lncRNA in macrophage nuclei. This study aims to identify serum lncRNA PELATON as a biomarker for assessing the incidence and prognosis of ACS. Levels of serum lncRNA PELATON were detected by real-time polymerase chain reaction (RT-PCR) in patients with ACS and healthy individuals. The clinical significance of lncRNA PELATON in patients with ACS was assessed by analyzing receiver operating characteristic and survival curves. The serum levels of lncRNA PELATON in patients with ACS were significantly higher than those in healthy individuals. LncRNA PELATON expression was positively correlated with the expression levels of high sensitivity C-reactive protein (hs-CRP), cardiac troponin T (cTnT) and creatine kinase MB (CK-MB) (p < 0.05). LncRNA PELATON can be used as a potential diagnostic index with an AUC of 0.706 for unstable angina pectoris (UA), 0.782 for acute non-ST-segment elevation myocardial infarction (NSTEMI) and 0.900 for acute ST-segment elevation myocardial infarction (STEMI). The incidence of major cardiovascular events in patients with ACS with high lncRNA PELATON expression was higher than that in those with low lncRNA PELATON expression. However, the mortality between patients in the high and low lncRNA PELATON groups was not significantly different. This study showed that higher levels of lncRNA PELATON were negatively correlated with the prognosis of ACS, revealing the potential of this measurement to serve as an index to assess the incidence and prognosis of ACS.
动脉粥样硬化是急性冠脉综合征（ACS）疾病的主要起源。先前的研究表明，动脉粥样硬化巨噬细胞调节富含斑块的长链非编码 RNA（lncRNA PELATON）是巨噬细胞核内的一种特异性 lncRNA。本研究旨在确定血清 lncRNA PELATON 作为评估 ACS 发生率和预后的生物标志物。通过实时聚合酶链反应（RT-PCR）检测 ACS 患者和健康个体的血清 lncRNA PELATON 水平。通过分析接收者操作特征和生存曲线评估 lncRNA PELATON 在 ACS 患者中的临床意义。ACS 患者的血清 lncRNA PELATON 水平明显高于健康个体。lncRNA PELATON 表达与高敏 C 反应蛋白（hs-CRP）、心肌肌钙蛋白 T（cTnT）和肌酸激酶同工酶 MB（CK-MB）的表达水平呈正相关（p<0.05）。lncRNA PELATON 可作为一种潜在的诊断指标，其对不稳定型心绞痛（UA）的 AUC 为 0.706，对急性非 ST 段抬高型心肌梗死（NSTEMI）的 AUC 为 0.782，对急性 ST 段抬高型心肌梗死（STEMI）的 AUC 为 0.900。高 lncRNA PELATON 表达的 ACS 患者主要心血管事件的发生率高于低 lncRNA PELATON 表达的患者。然而，高和低 lncRNA PELATON 组患者的死亡率无显著差异。本研究表明，较高水平的 lncRNA PELATON 与 ACS 的预后呈负相关，表明该测量值具有作为评估 ACS 发生率和预后的指标的潜力。
